In light of the incessant healthcare talk and reform on the imminent horizon, we’ve lately had fun discovering tiny new companies that illustrate some of the under-the-radar efforts of the medical community that might help reduce the cost of what has become a behemoth. (Oh, Congress, are you listening?) This week, that company [...]
As the International Society for Stem Cell Research (ISSCR) kicked off its annual meeting in Barcelona today, stem cell technology start-up iZumi Bio, a recent Fierce 15 finalist, grabbed headlines with the announcement that it had merged with Pierian, another stem cell technology start-up whose founders include three Harvard faculty members.
The newly formed company, called [...]
FierceBiotech today released its annual Fierce 15 list of the top fifteen emerging biotech companies, and editor John Carroll’s commentary on this year’s selection process was a bit surprising. In contrast to his initial fear, he says it was unexpectedly easy to find the top outfits, even given the rather disheartening state of the [...]
A Cambridge-based biopharma, developing a revolutionary class of drugs called Stapled Peptides, received some major backing from big pharma today. Fierce Biotech reported that Aileron Therapeutics landed $40 million in Series D funding from the venture arms of four of the world’s biggest pharma companies, including SR One (the corporate venture fund of GlaxoSmithKline), Novartis [...]